Highlights vom ERA 2025 in Wien

Dr. Marcus Säemann präsentiert seine Highlights vom ERA 2025 in Wien.

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
nejm.org/doi/abs/10.1056/NEJMoa2410659
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
nejm.org/doi/full/10.1056/NEJMoa2501006
ARO-C3, an investigational RNAi Therapeutic Targeting Complement C3, Reduces Proteinuria, Hematuria, andComplement Activity in IgAN Patients
ir.arrowheadpharma.com/static-files/71ace783-f…
Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy
sciencelibrary.sobi.com/sites/default/files/do…
Impact of acute eGFR dips and markers of disease severity on effects of empagliflozin on acute kidney outcome
era-apps.m-anage.com/era25/en-GB/pag/presentat…
youtube.com/watch?v=bX2Xtj_8mkg
renalandurologynews.com/reports/egfr-dip-empag…

Dieser Podcast wurde mit freundlicher Unterstützung von Boehringer Ingelheim RCV GmbH & Co realisiert.
Support the show (buzzsprout.com/2254118/support)